EPAD publishes a new paper on cognitive dispersion
On 7 September, the European Federation of Pharmaceutical Industries and Associations (EFPIA) held an event under the banner “Unlocking tomorrow’s cures” in Brussels, Belgium. The EFPIA Rentrée 2017 gathered six scientists working on groundbreaking, innovative and life-changing therapies:
- Dr Frank Bähner, Area Head Prophylactic Vaccines at Curevac, explained the advantages of mRNA vaccines where pandemics arise.
- Serge Van der Geyten (pictured), Director Neuroscience External Affairs at Janssen Pharmaceutical, presented EPAD with a talk entitled “Prevention of Alzheimer’s Dementia in Europe – the EPAD project”. He described the EPAD initiative, its aims and its progress to date.
- Alain Munafo, Global Head of Quantative Pharmacology at Merck explained the use of clinical trials in Multiple Sclerosis.
- Dr Alastair Coupe from Pfizer UK described the challenge of formulating better medicines for children.
- Ana Isabel Jiménez, Director of R&D at Sylentis, highlighted that oligonucleotides represent a novel approach to discovering new therapeutic agents.
- Luc Uylenbroeck, Head of New Patient Solutions and Portfolio Management at UCB, described how his company is able to create value for patients.
More information on the EFPIA Rentrée 2017: https://efpia.eu/news-events/the-efpia-view/blog-articles/07092017-efpia-s-rentree-2017-unlocking-tomorrow-s-cures/
Related posts
